Clinical Trials in New York State

Showing 14481-14500 of 16,145 trials

Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome

NCT00919113

A new device for interstitial cystitis is compared to inactive control to determine if it is safe and effective. The study lasts approximately 7 weeks with a 19-week follow-up period.

Interstitial CystitisPainful Bladder Syndrome

Watson Pharmaceuticals98 participantsStarted Jul 2009

Boulder, Colorado, United States • Denver, Colorado, United States • Farmington, Connecticut, United States +17 more locations

COMPLETEDPhase 279 miles

A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer

NCT00077857

This 2 arm study compared the efficacy and safety of label dose of capecitabine (Xeloda®) to that of a lower dose of Xeloda® plus docetaxel (Taxotere®) in patients with locally advanced or metastatic breast cancer after failure of chemotherapy with an anthracycline. Patients were randomized to receive either 1250 mg/m\^2 or 825 mg/m\^2 orally twice a day (po bid) on days 1-14 of each 3 week cycle, in combination with Taxotere® 75 mg/m2 intravenous (iv) on day 1 of each 3 week cycle. The anticipated time on study treatment was until disease progression and the target sample size was 440 individuals.

Breast Cancer

Hoffmann-La Roche470 participantsStarted Jul 2003

Birmingham, Alabama, United States • Hoover, Alabama, United States • Tucson, Arizona, United States +91 more locations

Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome

A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer

Find Trials by Condition in New York State

Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery

Drug Eluting Stent Registry of Thrombosis

Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer

Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients

Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy

Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer

Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection

A Pharmacokinetics, Pharmacodynamics and Safety Study of Rabeprazole in New Born Infants With Gastroesophageal Reflux Disease (GERD)

Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations

Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes

Treatment of Moderate to Severe Facial Acne Vulgaris

Cognitive REmediation After Trauma Exposure Trial = CREATE Trial

Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor

A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis

Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer

Pancreatic Cancer Serum and DNA Repository

Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors

Advisa MRI Clinical Study